Drug Search Results
More Filters [+]

Simenepag

Alternative Names: simenepag, agn-210669, agn210669, agn 210669
Latest Update: 2013-11-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: EP2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Simenepag

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Glaucoma, Open-Angle|Hypertension|Glaucoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01291108

P2

Completed

Hypertension|Glaucoma, Open-Angle

2011-10-01

NCT01001195

P2

Completed

Hypertension|Glaucoma, Open-Angle

2010-04-01

NCT00809848

P2

Completed

Glaucoma|Hypertension

2009-05-01

Recent News Events

Date

Type

Title